There are 2185 resources available
1786O - BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study
Presenter: Ewa Kalinka
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Abstract
802MO - Real-world comparison of overall survival between BCMA - bispecific and CAR-T therapies in multiple myeloma
Presenter: Junmin Song
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
443O - A perioperative study of safusidenib in patients with IDH1 mutated glioma
Presenter: James Whittle
Session: Proffered paper session: CNS tumours
Resources:
Abstract
803MO - CAR T cells reside in the bone marrow and inhibits healthy hematopoiesis
Presenter: Myriam BEN KHELIL
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
1959O - BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic urothelial carcinoma (UC)
Presenter: Dingwei Ye
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
444O - The prognostic impact of CDKN2A/B heterozygous deletions in IDH-mutant glioma
Presenter: Franziska Ippen
Session: Proffered paper session: CNS tumours
Resources:
Abstract
804MO - Gut microbiota composition is predictive of CAR-T cells response and its modulation enhances CAR-T cells activity
Presenter: Laura MARCOS-KOVANDZIC
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
1690O - NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study
Presenter: Eric Jonasch
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
LBA83 - PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
Presenter: Jordi Remon Masip
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Abstract
805MO - Real-world efficacy and safety of tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the early access program through the French DESCAR-T registry
Presenter: Loic Ysebaert
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract